Structural Analysis of Impurities in Pharmaceuticals Using Trap-Free 2D HPLC and the LCMSTM -9030

Significance of the Topic

Ensuring the safety and quality of pharmaceutical products requires accurate identification and quantification of trace impurities. Traditional HPLC-UV methods use nonvolatile buffers that cannot be directly interfaced with mass spectrometry, leading to laborious method redevelopment when migrating to LC/MS. A streamlined approach combining trap-free two-dimensional HPLC with a high-resolution quadrupole time-of-flight mass spectrometer (LCMS-9030) offers an efficient solution for structure elucidation of impurities without altering established chromatographic conditions.

Objectives and Study Overview

This application note describes an online workflow to:

• Maintain first-dimension separations under nonvolatile mobile phase conditions
• Capture and transfer target fractions via a trap-free loop into a second dimension using volatile solvents
• Perform high-accuracy MS and MS/MS analysis of atorvastatin calcium impurities
• Demonstrate structural assignment of pharmacopoeial impurities with minimal method development

Methodology and Instrumentation

• First-Dimension HPLC
  • Column: Shim-pack VP-ODS, 250 × 4.6 mm, 5 μm
  • Mobile Phase A: Citrate buffer pH 5.0/ACN/THF (4/1/1, v/v/v)
  • Mobile Phase B: ACN/THF (1/1, v/v); gradient from 7 % to 40 % B and return
  • Flow Rate: 1.43 mL/min; Temperature: 40 °C; Detection: UV 254 nm
• Trap-Free Fraction Capture
  • Peak capture loop isolates 16 chromatographic fractions including the main component and known impurities
• Second-Dimension HPLC
  • Column: Shim-pack XR-ODS, 50 × 2.0 mm, 2.2 μm
  • Mobile Phase A: 10 mM ammonium formate in water; B: Acetonitrile; gradient 10 % to 100 % B over 6.5 min
  • Flow Rate: 0.3 mL/min; Temperature: 40 °C; Detection: UV 254 nm and MS/MS
• Mass Spectrometry
  • Instrument: LCMS-9030 quadrupole time-of-flight
  • Ionization: ESI in positive and negative modes
  • Data Processing: High-accuracy mass assignment and MS/MS fragment interpretation with MS Workbook Suite (ACD/Labs)

Main Results and Discussion

The first-dimension UV chromatogram of atorvastatin calcium (approx. 16 min) revealed 16 peaks, all captured sequentially. Transfer to the second dimension allowed direct LCMS-9030 analysis under volatile conditions. Accurate mass data in both polarities matched theoretical values within ±1 ppm for key impurities (A, F, G, H, D) and atorvastatin itself. MS/MS of Impurity F (C40H48FN3O8) produced characteristic product ions (m/z 397.17, 453.20, 716.34), enabling confident structural assignment without additional off-line work.

Advantages and Practical Applications

• Eliminates reoptimization of chromatographic conditions between UV and MS methods
• Maintains native nonvolatile separations for robust impurity profiling
• Delivers high sensitivity, specificity, and accurate mass measurement in a single workflow
• Facilitates rapid structural confirmation of pharmacopoeial and unknown impurities

Future Trends and Application Possibilities

• Extension to a wider range of drug substances, excipients, and formulation impurities
• Integration with automated data analysis platforms and artificial intelligence for rapid fragment annotation
• Real-time in-line monitoring of impurities during process development and manufacturing
• Coupling with orthogonal ionization techniques or alternative high-resolution mass analyzers for deeper structural insight

Conclusion

The combination of trap-free 2D HPLC with the LCMS-9030 Q-TOF system streamlines impurity analysis by preserving established nonvolatile HPLC separations and enabling direct, high-accuracy MS and MS/MS characterization. This approach enhances productivity and confidence in regulatory compliance for pharmaceutical quality control and research.

Reference

T. Iida, Y. Inohana. Structural Analysis of Impurities in Pharmaceuticals Using Trap-Free 2D HPLC and the LCMS-9030. Shimadzu Application Note C185, First Edition, March 2019.